Steven W. King

President and CEO, Director

Steve King was appointed President and CEO of Peregrine Pharmaceuticals in March 2003 and has led the company into three Phase II clinical programs.  Mr. King joined the company in 1997 as Director of R&D.  In 2000, Steve was responsible for bringing the company’s biomanufacturing facility into full cGMP compliance and then launching Peregrine’s subsidiary Avid Bioservices. Prior to joining Peregrine, Steve worked with a company that was developing Vascular Targeting Agents and with UT Southwestern Medical Center with the inventor of Peregrine’s technology.  Steve holds BS and MS degrees in Biology from Texas Tech University.